Vasoactive intestinal polypeptide-secreting tumors (VIPomas) cause VIPoma syndrome, which is characterized by watery diarrhea, hypokalemia, and achlorhydria. The treatment options for metastatic VIPomas include somatostatin analogs, cytoreductive surgery, and chemotherapy. We report the case of a 54-year-old male who presented with a peripancreatic mass with multiple hepatic metastases on computed tomography. After resection, the peripancreatic mass was demonstrated pathologically to be a neuroendocrine tumor. Although the patient received systemic chemotherapy and somatostatin analogs for the hepatic metastatic masses, the tumor increased in size. The patient then experienced severe diarrhea, despite treatment with the somatostatin analogs. Elevated serum VIP levels (3,260 pg/mL) and typical symptoms confirmed the diagnosis of VIPoma. We performed hepatic artery embolization (HAE) to reduce the tumor volume and control his symptoms, which led to a very rapid symptomatic response. The patient has remained symptom-free for 18 months with repeated HAE. (Korean J Med 2014;87:363-368) 
INTRODUCTION
Vasoactive intestinal polypeptide (VIP)-secreting tumors (VIPomas) are very rare, with an annual incidence estimated to be < 0.2-0.5 per million individuals annually [1] . The excessive amounts of VIP secreted by these tumors causes watery diarrhea, hypokalemia, and achlorhydria (WDHA) syndrome [2] . Complete surgical resection is the only curative treatment for localized VIPomas. However, the treatment of advanced VIPomas is mostly palliative, such as systemic chemotherapy and the treatment of symptoms using cytoreductive surgery or somatostatin analogs [3, 4] . To our knowledge, the use of hepatic artery embolization (HAE) has been reported in only a small number of VIPoma cases [5] . Here, we report a 54-year-old male with metastatic VIPomas whose profound diarrhea and abnormal biochemical profiles were resolved successfully and rapidly using HAE.
CASE REPORT
A 54-year-old male presented with reduced stool caliber that had persisted for more than 1 month. Abdominal and pelvic computed tomography (CT) were performed in a community hospital, and revealed a 5-cm inhomogeneous enhancing mass anterior to the head of the pancreas, and four additional enhancing masses in hepatic segments VI, VII, and VIII. He was referred to our hospital, a tertiary referral hospital, for further work-up and treatment. A colonoscopy showed no abnormalities. According to the results of the enhanced CT, we determined that the tumors could be Castleman's disease, leiomyosarcomatosis, or multiple desmoid tumors. Because the masses seemed hypervascular on CT, a needle biopsy was not performed. Instead, we performed an exploratory laparotomy to confirm the diagnosis and reduce the tumor-mass effect to the greatest extent possible. We located and resected a 5-cm tumor, which was a hard omental lesion without invasion or infiltration to the adjacent structures. Eight metastatic hepatic masses were also detected, the largest of which was -2 cm in diameter. No lymph node metastasis was detected. Because the tumor stained positive for chromogranin, cytokeratin, and synaptophysin, it was diagnosed pathologically as a neuroendocrine tumor (Fig. 1) . Although no pancreatic mass was found on the CT or during the exploratory laparotomy, our histological analyses did not exclude the possibility of a metastatic pancreatic islet cell tumor. The neuroendocrine tumor was considered to be nonfunctioning because the patient had no remarkable symptoms (e.g., diarrhea, flushing, or hypoglycemia).
After the operation, the four enhancing liver masses were regarded as hepatic metastases, and additional tiny nodules of unknown significance and with omental infiltration anterior to gastric antrum were detected on CT. To control the residual hepatic metastases, the patient was treated using systemic 
DISCUSSION
In this case, HAE was very effective for relief of the symptoms of VIPoma, including diarrhea, hypokalemia, and acidosis. HAE can reduce the blood supply to tumor lesions and induce tumor cell death, which decreases the secretion of VIP by the tumor cells and amelioration of the VIPoma symptoms [7] . HAE might be effective not only for controlling the VIPoma symptoms but also for stabilizing tumor growth. However, the symptomatic responses might not always parallel the radiological responses, as evidenced by the slight increase in tumor size on a follow-up CT scans, despite the well-controlled symptoms.
To date, there have been only a small number of reports using HAE to relieve VIPoma symptoms [3, 5, 8] . Most reports of HAE in patients have been with neuroendocrine tumors that were not specified as VIPomas. HAE using only a vaso-occlusive material, such as Gelfoam, effectively decreased tumor size and hormone levels in most patients [7] .
Chemoembolization is a similar procedure, except that chemotherapeutic agents such as emulsified doxorubicin, 5-fluorouracil or cisplatin are administered directly into the hepatic artery.
Although chemoembolization was recently shown to be effective for unresectable malignant endocrine tumors, it might not offer therapeutic advantages over particulate embolization alone [9] . Because of the rarity of neuroendocrine tumors, no randomized studies have compared chemoembolization with embolization alone. We performed HAE on our patient rather than chemoembolization because the tumors were refractory to chemotherapy. We also predicted that hepatic arterial occlusion alone would be sufficient to inhibit the function of the hepatic metastatic tumors, which derive most of their blood supply from the hepatic artery.
Other treatment options for metastatic neuroendocrine tumors include chemotherapy and somatostatin analogs. The response rates to chemotherapy vary, and the effects with metastatic neuroendocrine tumors are often short lasting [10] . One randomized study of 106 patients with advanced islet cell tumors showed that combination therapy with streptozotocin and doxorubicin resulted in the best outcome, with a 69% response rate [11] . In a trial of 14 patients with endocrine pancreatic tumors, seven patients responded biochemically and five (36%) responded radiologically to the combination of etoposide and cisplatin, with a median response duration of 9 months [12] . Because streptozotocin is not available at our hospital, we selected the combination of etoposide and cisplatin, which was ineffective. Because of the small number of patients studied to date, there is no widely accepted standard chemotherapy regimen for neuroendocrine tumors. Moreover, most studies do not specify the specific type of neuroendocrine tumor, and the efficacy of systemic chemotherapy in patients with VIPomas is unclear.
Octreotide, a synthetic somatostatin analog, and its longacting release (LAR) preparations (e.g., Sandostatin LAR and lanreotide) can reduce hormone secretion by > 50% in 60-80% of patients with neuroendocrine tumors [13] . In addition, these compounds can reduce neoplastic proliferation in some patients by blocking the somatostatin receptors that are expressed in > 80% of neuroendocrine tumors [13] . Patients with VIPomas were reported to respond well to octreotide and its LAR preparations, with > 80% of patients showing the relief of symptoms such as diarrhea [14] . In addition, octreotide could stabilize disease [14] . Although < 20% of patients exhibit a radiological response to angiogenesis inhibitors (e.g., bevacizumab, sunitinib, sorafenib, and vatalanib) and mTOR inhibitors (e.g., everolimus and temsirolimus), these agents remain promising [14, 15] . Novel drugs that target some of these molecules are currently being assessed in early clinical trials for the treatment of neuroendocrine tumors.
In the current case, CT scans did not reveal the site of the primary tumor, suggesting that somatostatin receptor scintigraphy might have been needed to determine the primary site precisely [16] . Our patient was not diagnosed with a VIPoma initially because it might be difficult to distinguish from other neuroendocrine tumors pathologically. Rather than microscopic morphology, which can be ambiguous, the presence of elevated levels of serum VIP and symptoms typical of VIPomas are critical for the accurate diagnosis of these tumors [17] .
Because nearly complete symptomatic relief was achieved despite the presence of residual disease in some patients with
VIPomas that were treated using cytoreductive surgery or HAE, it is likely that there is a threshold level of VIP that is necessary to induce these symptoms. Our patient experienced periodic symptomatic exacerbation even after the first HAE, suggesting tumor regrowth and a resultant increase in VIP levels above the threshold concentration. However, repeated HAE ameliorated his symptoms. Generally, this procedure does not confer a survival advantage. Nevertheless, in our patient, who was refractory to somatostatin analogs and chemotherapy, HAE undoubtedly abrogated the life-threatening symptoms of VIPoma and allowed his continuing survival 18 months after the first HAE.
CONCLUSION
We encountered a patient with metastatic VIPoma who experienced diarrhea and abnormal biochemical profiles.
These symptoms were resolved successfully and rapidly using HAE, which resulted in long-term relief from symptoms. HAE should be considered as the first treatment option in patients with VIPomas and hepatic metastases that are unresectable and refractory to somatostatin analogs.
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